Martin M
Thromb Haemost. 1976 Dec 31;36(3):551-65.
A simple plasminogen determination method is presented. It is based upon the conversion of plasminogen into activator by large and constant amounts of streptokinase. The activator contained in a standard coagulum consisting of bovine fibrin, streptokinase, and a 1:40 dilution of human plasma converts the plasminogen adsorbed on bovine fibrin into plasmin. Lysis of the test coagulum is hereby induced. The speed of such lysis is limited by the concentration of the activator incorporated in the test coagulum. The variable component of the activator being human plasminogen, the speed of lysis is directly dependent upon the concentration of human plasminogen in the standard coagulum. Using the thromboelastograph according to Hartert in recording the test clot lysis times, this method of plasminogen determination was shown to be a simple and quick procedure. The standard deviation ranged from +/- 13,2 tp 68%, depending upon the plasminogen value to be measured (lower rates of error were attached to high, and higher rates of error to low, plasminogen concentrations). The biological variation of plasminogen values in a group of 26 men aged from 40 to 65 years was calculated to be +/- 21%. Both plasminogen and plasmin, its activated form, were exchangeable in the test, i.e. plasminogen determinations performed by activator assay did not differentiate between plasminogen and plasmin. There was no influence by varying anti-SK titers in the plasma up to a circulating antibody content of 2 million. Furthermore, plasma antiplasmins did not affect the plasminogen measuring system. Plasminogen tested by activator assay displayed values closely related to those achieved by immunochemical methods. Plasminogen measurements were performed in patients undergoing streptokinase and urokinase infusion treatment. 5,000 u streptokinase per hour, as well as 270,000 CTA-u urokinase per hour, infused over a period of 2 days produced a fall in plasminogen down to 30-60% of normal. In contrast, 100,000 u streptokinase per hour lowered the plasminogen concentration down to values of below 1%. The foregoing data indicate that plasminogen measurement, according to the principles outlined here (activator assay), may be regarded as a valuable and reliable method for the routine control of streptokinase and urokinase therapy.
本文介绍了一种简单的纤溶酶原测定方法。该方法基于大量恒定的链激酶将纤溶酶原转化为激活剂。由牛纤维蛋白、链激酶和1:40稀释的人血浆组成的标准凝块中所含的激活剂，可将吸附在牛纤维蛋白上的纤溶酶原转化为纤溶酶。由此引发测试凝块的溶解。这种溶解的速度受测试凝块中所含激活剂浓度的限制。激活剂的可变成分是人纤溶酶原，溶解速度直接取决于标准凝块中人纤溶酶原的浓度。使用根据哈特特方法的血栓弹性描记仪记录测试凝块的溶解时间，这种纤溶酶原测定方法被证明是一种简单快捷的程序。标准偏差范围为±13.2%至68%，这取决于要测量的纤溶酶原值（纤溶酶原浓度高时误差率较低，纤溶酶原浓度低时误差率较高）。计算得出一组年龄在40至65岁之间的26名男性纤溶酶原值的生物学变异为±21%。在测试中，纤溶酶原及其激活形式纤溶酶是可互换的，即通过激活剂测定进行纤溶酶原测定无法区分纤溶酶原和纤溶酶。血浆中抗链激酶滴度变化直至循环抗体含量达200万时均无影响。此外，血浆抗纤溶酶不影响纤溶酶原测量系统。通过激活剂测定测试的纤溶酶原显示的值与通过免疫化学方法获得的值密切相关。对接受链激酶和尿激酶输注治疗的患者进行了纤溶酶原测量。每小时输注5000单位链激酶以及每小时输注270000CTA单位尿激酶，持续2天，可使纤溶酶原降至正常水平的30 - 60%。相比之下，每小时输注100000单位链激酶可使纤溶酶原浓度降至1%以下。上述数据表明，根据此处概述的原理（激活剂测定）进行纤溶酶原测量，可被视为链激酶和尿激酶治疗常规监测的一种有价值且可靠的方法。
